American Society of Hirudotherapy

Catastrophic antiphospholipid syndrome: Lessons from the "CAPS Registry".

Review published in Medicina clinica (2024)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical TrialsDrug DevelopmentRodriguez-Pintó et al. · Medicina clinica, 2024

Abstract

The catastrophic antiphospholipid syndrome (CAPS) is a rare life-threatening clinical condition that represents the most severe clinical presentation of the antiphospholipid syndrome (APS). It was first described in 1992 in a group of patients that presented with multiorgan involvement and microangiopathic features of APS. Most of the current knowledge of CAPS comes from the analysis of all cases collected at the "CAPS Registry" that was created in 2000 to perform studies on this condition. Most cases are triggered by a prothrombotic situation that leads to a multiorgan thrombosis and a cytokine storm. The analysis of cases included in the "CAPS Registry" has shown that the triple therapy with anticoagulation, glucocorticoids, and plasma exchange and/or intravenous immunoglobulins is associated to a better prognosis of CAPS. The improvement of the knowledge allowed a decrease from the 50% mortality rate reported in the first series to 25-30% in the most recent publications.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAntiphospholipid SyndromeHumansRegistriesCatastrophic IllnessPlasma ExchangeAnticoagulantsImmunoglobulins, IntravenousGlucocorticoidsFemaleThrombosisCombined Modality TherapyPrognosis

Summary

The catastrophic antiphospholipid syndrome (CAPS) is a rare life-threatening clinical condition that represents the most severe clinical presentation of the antiphospholipid syndrome (APS). It was first described in 1992 in a group of patients that presented with multiorgan involvement and...

Why This Matters for Hirudotherapy

This review draws on the international CAPS Registry to summarize knowledge about catastrophic antiphospholipid syndrome, noting that triple therapy with anticoagulation, glucocorticoids, and plasma exchange and/or intravenous immunoglobulins improves prognosis, reducing mortality from approximately 50% to 25–30%. It is relevant to ASH's domain only in the broad context of anticoagulation as part of a therapeutic regimen for thrombotic disease. The abstract does not mention leeches, hirudotherapy, or hirudin-based agents. Its relevance is indirect.

Citation

Catastrophic antiphospholipid syndrome: Lessons from the "CAPS Registry".

Rodriguez-Pintó et al. · Medicina clinica, 2024

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.